GB1597882A - Injectable pharmaceutical compositions comprising pteridine derivatives - Google Patents
Injectable pharmaceutical compositions comprising pteridine derivatives Download PDFInfo
- Publication number
- GB1597882A GB1597882A GB26630/80A GB2663080A GB1597882A GB 1597882 A GB1597882 A GB 1597882A GB 26630/80 A GB26630/80 A GB 26630/80A GB 2663080 A GB2663080 A GB 2663080A GB 1597882 A GB1597882 A GB 1597882A
- Authority
- GB
- United Kingdom
- Prior art keywords
- pharmaceutical compositions
- pteridine
- triamterene
- triamino
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 11
- 125000001042 pteridinyl group Chemical class N1=C(N=CC2=NC=CN=C12)* 0.000 title description 2
- 239000000203 mixture Substances 0.000 claims description 7
- 239000004480 active ingredient Substances 0.000 claims description 5
- QNJVMSASTUDLGC-UHFFFAOYSA-N 4-(2,4,7-triaminopteridin-6-yl)phenol Chemical compound NC1=NC2=NC(N)=NC(N)=C2N=C1C1=CC=C(O)C=C1 QNJVMSASTUDLGC-UHFFFAOYSA-N 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- XXFIGLAYTZCDPY-UHFFFAOYSA-N 6-(4-methoxyphenyl)pteridine-2,4,7-triamine Chemical compound C1=CC(OC)=CC=C1C1=NC2=C(N)N=C(N)N=C2N=C1N XXFIGLAYTZCDPY-UHFFFAOYSA-N 0.000 claims description 2
- 150000001768 cations Chemical class 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- -1 pteridine compound Chemical class 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- FNYLWPVRPXGIIP-UHFFFAOYSA-N Triamterene Chemical compound NC1=NC2=NC(N)=NC(N)=C2N=C1C1=CC=CC=C1 FNYLWPVRPXGIIP-UHFFFAOYSA-N 0.000 description 18
- 150000001875 compounds Chemical class 0.000 description 17
- 229960001288 triamterene Drugs 0.000 description 15
- 230000001882 diuretic effect Effects 0.000 description 10
- 239000002934 diuretic Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 5
- 230000000894 saliuretic effect Effects 0.000 description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- 240000006365 Vitis vinifera Species 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 230000003293 cardioprotective effect Effects 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 2
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 2
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 229960002478 aldosterone Drugs 0.000 description 2
- XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 150000007658 benzothiadiazines Chemical class 0.000 description 2
- 230000006957 competitive inhibition Effects 0.000 description 2
- 229940030606 diuretics Drugs 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 230000001631 hypertensive effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 229910001414 potassium ion Inorganic materials 0.000 description 2
- 150000003195 pteridines Chemical class 0.000 description 2
- 210000003079 salivary gland Anatomy 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- HXKKHQJGJAFBHI-UHFFFAOYSA-N 1-aminopropan-2-ol Chemical class CC(O)CN HXKKHQJGJAFBHI-UHFFFAOYSA-N 0.000 description 1
- PACGLQCRGWFBJH-UHFFFAOYSA-N 2-(4-methoxyphenyl)acetonitrile Chemical compound COC1=CC=C(CC#N)C=C1 PACGLQCRGWFBJH-UHFFFAOYSA-N 0.000 description 1
- ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 description 1
- XLQQJSWJHHKLOK-UHFFFAOYSA-N 5-nitrosopyrimidine-2,4,6-triamine Chemical compound NC1=NC(N)=C(N=O)C(N)=N1 XLQQJSWJHHKLOK-UHFFFAOYSA-N 0.000 description 1
- 208000005223 Alkalosis Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000007530 Essential hypertension Diseases 0.000 description 1
- 208000013038 Hypocalcemia Diseases 0.000 description 1
- 208000019025 Hypokalemia Diseases 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 150000001243 acetic acids Chemical class 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 230000002340 alkalosis Effects 0.000 description 1
- 229960002576 amiloride Drugs 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- DXYNDDQQWQTPJH-UHFFFAOYSA-N butan-2-one;propan-2-one;hydrate Chemical compound O.CC(C)=O.CCC(C)=O DXYNDDQQWQTPJH-UHFFFAOYSA-N 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 229960002155 chlorothiazide Drugs 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229960002887 deanol Drugs 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 150000002169 ethanolamines Chemical class 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 150000004674 formic acids Chemical class 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 150000002357 guanidines Chemical class 0.000 description 1
- 229960002003 hydrochlorothiazide Drugs 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000000705 hypocalcaemia Effects 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 125000005440 p-toluyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C(*)=O)C([H])([H])[H] 0.000 description 1
- 210000003540 papillary muscle Anatomy 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- CPNGPNLZQNNVQM-UHFFFAOYSA-N pteridine Chemical class N1=CN=CC2=NC=CN=C21 CPNGPNLZQNNVQM-UHFFFAOYSA-N 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
- 229960002256 spironolactone Drugs 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
- C07D475/08—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Springs (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19772700073 DE2700073A1 (de) | 1977-01-03 | 1977-01-03 | Pteridinverbindungen mit pharmazeutischer wirksamkeit |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB1597882A true GB1597882A (en) | 1981-09-16 |
Family
ID=5998070
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB67/78A Expired GB1597881A (en) | 1977-01-03 | 1978-01-03 | 2,4,7-triamino-6-(p-substituted phenyl)-pteridines their preparation and pharmaceutical compositions thereof |
| GB26630/80A Expired GB1597882A (en) | 1977-01-03 | 1978-01-03 | Injectable pharmaceutical compositions comprising pteridine derivatives |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB67/78A Expired GB1597881A (en) | 1977-01-03 | 1978-01-03 | 2,4,7-triamino-6-(p-substituted phenyl)-pteridines their preparation and pharmaceutical compositions thereof |
Country Status (13)
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4910203A (en) * | 1984-03-02 | 1990-03-20 | Christian Rietzel | Pteridine compounds |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2815442A1 (de) * | 1978-04-10 | 1979-10-18 | Roehm Pharma Gmbh | Rasch wirksame diuretika |
| DE3505253C2 (de) * | 1985-02-15 | 1995-04-27 | Seitz Enzinger Noll Masch | Flaschenverteilstation zum Umformen eines angeförderten einspurigen Flaschenstroms zu einem abzufördernden breiten Flaschenstrom |
| HU214331B (hu) * | 1992-06-17 | 1998-03-02 | Gyógyszerkutató Intézet Kft. | Eljárás piperazin- és homopiperazinszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására |
| EP4408252A1 (en) | 2021-09-28 | 2024-08-07 | Ambu A/S | An endoscope |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3081230A (en) | 1960-09-08 | 1963-03-12 | Smith Kline French Lab | Diuretic and antihypertensive triaminoarylpteridines |
| FR1014M (fr) * | 1960-11-05 | 1961-12-26 | Smith Kline French Lab | Compositions médicinales a base de 6-aryl-2,4,7-triaminoptéridine. |
-
1977
- 1977-01-03 DE DE19772700073 patent/DE2700073A1/de active Granted
- 1977-10-20 AT AT748877A patent/AT353798B/de not_active IP Right Cessation
- 1977-12-28 JP JP15864777A patent/JPS5384993A/ja active Granted
- 1977-12-29 ES ES465578A patent/ES465578A1/es not_active Expired
- 1977-12-29 DD DD77203010A patent/DD136837A5/xx unknown
- 1977-12-30 FR FR7739798A patent/FR2420345B1/fr not_active Expired
-
1978
- 1978-01-01 CH CH1359977A patent/CH633962A5/de not_active IP Right Cessation
- 1978-01-02 SE SE7800048A patent/SE436203B/sv not_active IP Right Cessation
- 1978-01-03 NL NL7800067A patent/NL190573C/xx not_active IP Right Cessation
- 1978-01-03 CA CA294,246A patent/CA1099714A/en not_active Expired
- 1978-01-03 ZA ZA00780012A patent/ZA7812B/xx unknown
- 1978-01-03 GB GB67/78A patent/GB1597881A/en not_active Expired
- 1978-01-03 AU AU32140/78A patent/AU515140B2/en not_active Expired
- 1978-01-03 GB GB26630/80A patent/GB1597882A/en not_active Expired
-
1980
- 1980-02-14 FR FR8003308A patent/FR2445331A1/fr active Granted
-
1982
- 1982-09-06 CH CH528882A patent/CH639663A5/fr not_active IP Right Cessation
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4910203A (en) * | 1984-03-02 | 1990-03-20 | Christian Rietzel | Pteridine compounds |
Also Published As
| Publication number | Publication date |
|---|---|
| CH633962A5 (en) | 1983-01-14 |
| AT353798B (de) | 1979-12-10 |
| FR2445331B1 (enrdf_load_stackoverflow) | 1983-01-28 |
| FR2420345A1 (enrdf_load_stackoverflow) | 1979-10-19 |
| AU3214078A (en) | 1979-07-12 |
| ZA7812B (en) | 1978-10-25 |
| JPS631314B2 (enrdf_load_stackoverflow) | 1988-01-12 |
| DE2700073C2 (enrdf_load_stackoverflow) | 1991-03-21 |
| GB1597881A (en) | 1981-09-16 |
| SE436203B (sv) | 1984-11-19 |
| ATA748877A (de) | 1979-05-15 |
| JPS5384993A (en) | 1978-07-26 |
| FR2445331A1 (fr) | 1980-07-25 |
| DE2700073A1 (de) | 1978-07-13 |
| AU515140B2 (en) | 1981-03-19 |
| NL190573B (nl) | 1993-12-01 |
| NL7800067A (nl) | 1978-07-05 |
| DD136837A5 (de) | 1979-08-01 |
| NL190573C (nl) | 1994-05-02 |
| SE7800048L (sv) | 1978-07-04 |
| CH639663A5 (en) | 1983-11-30 |
| ES465578A1 (es) | 1979-01-01 |
| FR2420345B1 (enrdf_load_stackoverflow) | 1983-01-28 |
| CA1099714A (en) | 1981-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0495776A1 (en) | STABILIZED NITRIC OXIDE-PRIMARY AMINE COMPLEXES USEFUL AS CARDIOVASCULAR AGENTS. | |
| EP0324387A2 (en) | Composition for treatment of ischemic disorder in organs | |
| US3666856A (en) | Treating immune response with amino purine derivatives | |
| US4328229A (en) | Anti-cancer composition for delivering 5-fluorouracil to cancer tissues | |
| US4081534A (en) | Amino purine nucleosides as autoimmune suppressant agents | |
| US5219846A (en) | Treatment of human tumors utilizing compounds having a phosphoamides linkage or enol phosphate linkage | |
| US4914105A (en) | Anti-cancer compositions for delivering 5-fluorouracil | |
| EP0023704A2 (en) | Novel dosage forms containing propanolol | |
| GB1597882A (en) | Injectable pharmaceutical compositions comprising pteridine derivatives | |
| US4507301A (en) | Anti-cancer composition for delivering 5-fluorouracil | |
| US4719213A (en) | Anti-cancer composition for delivering 5-fluorouracil | |
| US4252809A (en) | Substituted pteridine compounds and pharmaceutical compositions containing the same | |
| EP0476711A2 (en) | Use of 5-fluorouracil for the treatment of AIDS | |
| CA1110543A (en) | Injectable pharmaceutical compositions comprising pteridine derivatives | |
| EP0350650A1 (en) | Therapeutic composition for hepatic encephalopathy | |
| US4590197A (en) | 9,10-substituted 2-mesitylimino-3-alkyl-3,4,6,7-tetra-hydro-2H-pyrimido(6,1-a)isoquinolin-4-ones, and their use as medicaments | |
| CA1139670A (en) | Process and composition for reducing blood pressure in animals | |
| US4315003A (en) | Compositions containing azo compounds and use thereof for therapeutic treatment | |
| EP0120019A1 (de) | Pharmazeutische zubereitungen mit zytostatischer wirkung. | |
| EP0783884A1 (en) | Preventive and remedy for diarrhea | |
| US5922838A (en) | Cyclic hexapeptide compounds | |
| GB1582014A (en) | Pteridine compounds | |
| US20040142882A1 (en) | Use of glycyrrhizin and its derivatives as RANTES inducers | |
| AT352740B (de) | Verfahren zur herstellung von neuen pteridin- verbindungen | |
| PL96042B1 (pl) | Sposob wytwarzania nowych aminopochodnych azydofenoli |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PS | Patent sealed [section 19, patents act 1949] | ||
| PE20 | Patent expired after termination of 20 years |
Effective date: 19980102 |